Galway medtech Luminate Medical has raised €18 million in a series A funding round. The latest cash inflow was co-led by US financiers Lachy Groom and Artis Ventures, with participation from Western Alliance Life Sciences. The new backers join existing investors 8VC, Y Combinator, Atlantic Bridge, Faber, SciFounders, Elkstone and others. The latest investment brings the total capital investment to over €43 million.

The company intends to use the funds to launch access to home cancer care at 40 partner oncology clinics, before launching its novel patient-led home infusion technology later in the year.

According to Luminate, the announcement comes at a time in which healthcare organisations in the US are expressing a keen interest in participating in Luminate’s Lotus at-home cancer treatment programme, alongside the launch of the company’s peripheral neuropathy prevention trial at St James’ Hospital, Dublin.

According to a statement from Luminate Medical, “clinical studies of the Lotus auto-injector and monitoring technologies, designed to enable patient-led self-administration of some anti-cancer therapies, are expected to begin in the first half of 2026.”

The company plans to employ an additional 130 employees over the course of the next three years, and is actively recruiting for roles in software development, electronics, clinical research, mechanical design and manufacturing to join the team at its Galway office and for oncology nurses, pharmacists and healthcare administrators to join its remote US workforce.

Commenting on the funding news, Aaron Hannon, the CEO and co-founder of the company said: “Cancer doesn’t need to mean life-changing financial, time or physical burdens on patients. Luminate’s care model and technology can help providers stay in control of the patient’s treatment while scaling their impact to meet the growing future demand for cancer care. 

“Importantly, we’re doing that while reducing the cost of care to the healthcare system, but most significantly, to the patient. This fresh injection of funding helps us to capitalise on a growing demand from providers and managed care partners to work with us in delivering better outcomes for patients.”

Luminate was founded in 2018 by Aaron Hannon, Dr Barbara Oliveira and Prof Martin O’Halloran at the University of Galway. In April of last year, as part of the Disruptive Technologies Innovation Fund programme, the organisation’s Lotus project was awarded €6.4 million to develop a smart system that will facilitate at-home anti-cancer treatment that allows patients to be monitored and treated in the comfort of their own home.